ASH 2022 | Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting

Name: Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting
Uploaded: 2022-12-10T00:00:00Z
Duration: 43 s

Shernan Holtan • 10 Dec 2022

ASH 2022

General Cyclophosphamide Mycophenolate mofetil Tacrolimus

BMT CTN 1703

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, briefly discusses the results of a Phase II study evaluating post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil (MMF) for graft-versus-host disease (GvHD) in the myeloablative transplant setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.